Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Assets Average (2021 - 2025)

Cytek Biosciences (CTKB) has disclosed Assets Average for 5 consecutive years, with $494.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Assets Average changed N/A year-over-year to $494.1 million, compared with a TTM value of $494.1 million through Sep 2025, changed N/A, and an annual FY2024 reading of $497.0 million, down 1.97% over the prior year.
  • Assets Average was $494.1 million for Q3 2025 at Cytek Biosciences, roughly flat from $493.3 million in the prior quarter.
  • Across five years, Assets Average topped out at $524.8 million in Q2 2023 and bottomed at $342.3 million in Q3 2021.
  • Average Assets Average over 5 years is $486.2 million, with a median of $495.1 million recorded in 2022.
  • The sharpest move saw Assets Average soared 44.92% in 2022, then decreased 5.51% in 2024.
  • Year by year, Assets Average stood at $458.8 million in 2021, then grew by 11.02% to $509.4 million in 2022, then dropped by 0.48% to $506.9 million in 2023, then decreased by 2.7% to $493.3 million in 2024, then grew by 0.17% to $494.1 million in 2025.
  • Business Quant data shows Assets Average for CTKB at $494.1 million in Q3 2025, $493.3 million in Q1 2024, and $506.9 million in Q4 2023.